Sidney Kimmel Cancer Center at Jefferson | Strategic Alliance Partners

Latest from Sidney Kimmel Cancer Center at Jefferson


Gastrointestinal Malignancies: Chaired by Steven J. Cohen, MD

February 03, 2021

Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of gastrointestinal malignancies.

Giri and Gomella on Fostering a New Framework for Genetic Testing Guidelines in Prostate Cancer

September 14, 2020

In our exclusive interview, Dr. Giri and Dr. Gomella discuss the rationale to create the first multidisciplinary, consensus-driven framework for prostate cancer genetic testing, the importance of having a multidisciplinary team weigh in on the recommendations, and key aspects of the guidelines that could have clinical implications for men in this space.

Dr. Kelly on Efficacy of Radium-223 Dichloride and Niraparib in Patients With mCRPC

June 10, 2020

William K. Kelly, DO, discusses results from a phase 1b dose-finding study evaluating the combination of radium-223 dichloride (Xofigo) plus niraparib (Zejula) in patients with metastatic castration-resistant prostate cancer.

DNA-PK as an Emerging Target in Prostate Cancer

May 07, 2020

Karen E. Knudsen, PhD, chair and Hilary Koprowski Professor, Department of Cancer Biology, professor of cancer biology, urology, medical oncology, and radiation oncology, and enterprise director, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, discusses DNA-dependent protein kinase (DNA-PK) as an emerging target in prostate cancer.

Dr. Gomella on the Evolution of Genetic Testing in Prostate Cancer

May 07, 2020

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the evolution of genetic testing in prostate cancer.

Dr. Gomella on Potential Impact of Targeted Therapy Approvals on Genetic Testing in Prostate Cancer

April 03, 2020

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the potential impact of targeted therapy approvals on the use of genetic testing in prostate cancer.

Dr. Gomella on the Evolution of AR Inhibitors in Prostate Cancer

March 19, 2020

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the evolution of androgen receptor (AR) inhibitors in prostate cancer.